Immix Biopharma

Youtube Subscribe

Open: 3.22 Close: 3.06 Change: -0.16

You're running out of time to find out about Immix Biopharma using an AI.

How much time have you spent trying to decide whether investing in Immix Biopharma? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Immix Biopharma are: …

Concept Map

Semantic Network

Stock Summary

Immix Biopharma, Inc. engages in developing tissue-specific therapeutics in oncology and inflammation. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft.

Today's Summary

Immix Biopharma Inc (IMMX) stock is lower by -2.01% while the S&P 500 is up 0.31% as of 10:58 AM on Friday, Feb 9. Immix biopharma awarded european union orphan drug designation for nxc-201 in al amyloidosis.

Today's News

Immix Biopharma Inc (IMMX) stock is lower by -2.01% while the S&P 500 is up 0.31% as of 10:58 AM on Friday, Feb 9. Immix biopharma awarded european union orphan drug designation for nxc-201 in al amyloidosis. Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”,. “We” or “Us”) is a clinical-stage biopharmaceutical company advancing personalized therapies. Immix Biopharma is a clinical-stage biopharmaceutical company developing Tissue-Specific Therapeutics in oncology and inflammation. Immix biopharma signs definitive $15m titan partnership deal. Immix Biopharma awarded european union orphan drug designation for nxc-201 in al amyloidosis. Immix biopharma announces new offering, sparks investor interest. Immix Biopharma suspends stock offering pending new prospectus. Nasdaq Futures 17,941.75 -23.25 (-0.12%) Russell 2000 Futures 2,053.60 -1.40 (-1.07%) Crude Oil 77.08 +0.16 (+0.21%) Gold.

Stock Profile

"Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California."

Keywords

This document will help you to evaluate Immix Biopharma without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Immix Biopharma are: Immix, Biopharma, biopharma, Inc, stock, award, european, and the most common words in the summary are: biopharma, follow, immix, nasdaq, stock, inc, company, . One of the sentences in the summary was: Immix biopharma awarded european union orphan drug designation for nxc-201 in al amyloidosis.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #biopharma #follow #immix #nasdaq #stock #inc #company.

Read more →

Youtube Subscribe

---